Figure 2.
Figure 2. The glucose analogs 2-deoxyglucose and 3-O-methylglucose inhibit cell growth in hematologic and nonhematologic malignancies. Relative growth of various cell lines in response to 2-deoxyglucose or 3-O-methylglucose or imatinib mesylate was calculated as a percentage compared with cells left untreated. (A) Cell growth of the BCR-ABL-expressing hematopoietic BaF3 and MO7e cell lines was determined. Cells were treated for 1 day with the indicated amounts of 2-deoxyglucose (left panels) or 3-O-methylglucose (right panels) in the absence (♦) or presence (▪) of imatinib mesylate (0.5 μM). (B-D) Cell growth of (B) Ph+ cell lines, (C) leukemia and lymphoma cell lines, and (D) solid-tumor cell lines was determined as indicated. Cells (n = 4) were treated for 3 days with either glucose (▴), 3-O-methylglucose (▪), or 2-deoxyglucose (♦) (B-C). Error bars indicate standard error of the mean.

The glucose analogs 2-deoxyglucose and 3-O-methylglucose inhibit cell growth in hematologic and nonhematologic malignancies. Relative growth of various cell lines in response to 2-deoxyglucose or 3-O-methylglucose or imatinib mesylate was calculated as a percentage compared with cells left untreated. (A) Cell growth of the BCR-ABL-expressing hematopoietic BaF3 and MO7e cell lines was determined. Cells were treated for 1 day with the indicated amounts of 2-deoxyglucose (left panels) or 3-O-methylglucose (right panels) in the absence (♦) or presence (▪) of imatinib mesylate (0.5 μM). (B-D) Cell growth of (B) Ph+ cell lines, (C) leukemia and lymphoma cell lines, and (D) solid-tumor cell lines was determined as indicated. Cells (n = 4) were treated for 3 days with either glucose (▴), 3-O-methylglucose (▪), or 2-deoxyglucose (♦) (B-C). Error bars indicate standard error of the mean.

Close Modal

or Create an Account

Close Modal
Close Modal